Eli Lilly has launched a fresh method that will allow self-shell out clients to purchase the weight-loss drug Zepbound for as small as $399 a month—fewer than half the checklist price of other incretin medicines useful for people with obesity.Medication solutions presented through the pharmacy arm of LillyDirect are restricted to Zepbound, an inj